Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Go back to Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)| (NASDAQ: JAGX) | Delayed: 1.08 -0.25 (18.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.33 | 52 Week High | $4.60 | |||
| Open | $1.33 | 52 Week Low | $0.81 | |||
| Day High | $1.33 | P/E | N/A | |||
| Day Low | $0.97 | EPS | $0.00 | |||
| Volume | 216,791 | |||||
